

Carbon Reduction Plan

Supplier name: ...Novartis Pharmaceuticals UK Ltd

Publication date: November 2023

Commitment to achieving Net Zero

Novartis Pharmaceuticals UK Ltd as part of Novartis AG are committed to achieving Net Zero emissions by 2040.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2022	
Additional Details relating to the Baseline Emissions calculations.	
Currently Novartis' emissions data is calculated using methodologies approved by the Science Based Target initiative. This reporting is reported at the global enterprise level (Novartis AG) and therefore data in this CRP submission will utilise this data. In future years we anticipate that as our ESG reporting capabilities mature we may be able to provide more granular UK specific data and if this occurs, will provide clarifications on any deviations from the baseline identified in this document.	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	343,149
Scope 2	147,501

Scope 3 (Included Sources)	7,663,118 SBTI calculated Enterprise level values for the following Scope 3 source categories: <ol style="list-style-type: none">1. Purchased goods and services2. Capital goods3. Fuel and energy related activities4. Upstream transportation and distribution5. Waste generated in operations6. Business Travel7. Employee Commute9. Downstream transportation and distribution11. Use of sold products12. End of life treatment of sold products
Total Emissions	8,153,768

Current Emissions Reporting

Reporting Year: 2022	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	343,149
Scope 2	147,501
Scope 3 (Included Sources)	7,663,118 SBTi calculated Enterprise level values for the following Scope 3 source categories: <ol style="list-style-type: none"> 1. Purchased goods and services 2. Capital goods 3. Fuel and energy related activities 4. Upstream transportation and distribution 5. Waste generated in operations 6. Business Travel 7. Employee Commute 9. Downstream transportation and distribution 11. Use of sold products 12. End of life treatment of sold products
Total Emissions	8,153,768

Emissions reduction targets

In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets. We aim to be carbon neutral in our own operations by 2025 and fully carbon neutral across the value chain by 2030. We are also in process of validating our near term targets with SBTi

Carbon Reduction Projects

Globally Novartis is running a wide range of projects across the company to achieve our ambition to be Net Zero by 2040. Our steps to achieve that include a plan to:

- Become carbon neutral in our own operations¹ by 2025
- Include environmental criteria in all supplier contracts by 2025
- Become carbon neutral (Scope 1, 2 and 3) by 2030 and achieve net zero carbon emissions across our value chain by 2040 in accordance with SBTi net-zero standard.

We are a signatory of [The Climate Pledge](#) and a member of [RE100](#), to help accelerate progress toward 100% renewable electricity, and [EV100](#), helping drive the transition to electric vehicles.

We are committed to using 100% renewable electricity across our operations by 2025. In 2022, we had renewable power purchase agreements in place to cover electricity consumption across our operations in Europe (including the UK) and North America. We are also implementing multiple projects to reduce our thermal emissions i.e emissions from combustion of fossil fuels across the company. Some of the projects include implementation of biomass based steam generation, conversion to electric boilers and use of renewable electricity to operate them, solar thermal installation etc.

In the UK organisation, one of our single largest areas of emissions, is the carbon footprint of our fleet vehicles. We are therefore working on an ambitious plan to transition this to a low Carbon fleet by 2025.

In the future we hope to implement further measures such as:

- Develop strategies and solutions to reduce the GHG emissions of business travel and commuting
- Work across industry to reduce the GHG emissions of Clinical Trials
- Partner with organizations to implement renewable power and further reduce our reliance on fossil fuels

¹ Scope 1 and 2 from energy

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard² and uses the appropriate Government emission conversion factors for greenhouse gas company reporting³.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard⁴.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

DocuSigned by:


.....3D5A8A77C33845D.....

06-Nov-23 | 2:33:05 PM GMT

Date:

²<https://ghgprotocol.org/corporate-standard>

³<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

⁴<https://ghgprotocol.org/standards/scope-3-standard>